Innovative Medicines Initiative

Da Volterra, The Medicines Company join COMBACTE-NET to combat antimicrobial resistance

Friday, November 18, 2016

The Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) project COMBACTE-NET announces that two new pharmaceutical companies, Da Volterra and The Medicines Company, have joined the project as partners. Together with the existing partners the new partners will closely collaborate to further strengthen the public-private partnership aiming to combat the worldwide growing problem of antimicrobial resistance.

[Read More]

Three resonating patient-centric initiatives

Friday, July 1, 2016

Sponsor companies are piloting patient-centric initiatives at a furious pace. Although few initiatives designed to engage patients as clinical research partners have achieved widespread adoption, several are making substantial inroads. In this issue, CenterWatch profiles three major patient-centric initiatives that appear to be resonating across the clinical research enterprise.

[Read More]

European patient engagement in critical condition

Thursday, October 15, 2015

Western Europe boasts one of the largest and most active markets for clinical trials. Indeed, more than one in five active clinical investigators is based in Western Europe, and the growth in sponsor spending there now outpaces that in the U.S.

[Read More]

New Innovative Medicines Initiative project launched to combat carbapenem resistance

Wednesday, March 25, 2015

Eighteen European academic partners and three pharmaceutical companies are launching a new project under the Innovative Medicines Initiative (IMI) funded New Drugs 4 Bad Bugs (ND4BB) program. COMBACTE-CARE (Combating Bacterial resistance in Europe-Carbapenem-Resistance) will bring highly innovative studies and activities related to the treatment of patients with infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). Being very difficult to treat and sometimes deadly, CRE are considered to be one of the most dangerous resistant bacteria in the world. University Medical Center Utrecht is the project’s managing entity.

[Read More]

Johnson & Johnson forms Ebola vaccine development consortia

Monday, January 19, 2015

Johnson & Johnson has formed a consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than $116 million from the Ebola+ program to support the development, manufacturing and patient education for the vaccine regimen.

[Read More]

EFPIA, Innovative Medicines Initiative form $348.2M Ebola+ program

Friday, November 7, 2014

European Federation of Pharmaceutical Industries and Associations (EFPIA), a representative of the pharmaceutical industry operating in Europe, its specialized group Vaccines Europe and the Innovative Medicines Initiative have launched a $348.2 million call for proposals for an Innovative Medicines Initiative (IMI) program aimed to address the current Ebola crisis. The Ebola+ program will bring together the pharma industry and researchers in a collaborative program aimed to cover the current outbreak, as well as future needs in the space of hemorrhagic fevers.

[Read More]

New IMI project to incorporate real-life data into drug development

Thursday, March 13, 2014

The Innovative Medicines Initiative (IMI) has launched a new project called GETREAL that will investigate new ways to integrate data from real-life settings, such as clinics, into drug development in Europe. This will assist healthcare decision makers in choosing how best to grant patients access to a new treatment and help pharmaceutical companies make better decisions during drug development.

[Read More]